Compare Pfizer Inc (PFE) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Pfizer Inc trades at $28.28 (market cap $158.56B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $59.76 (market cap $168.50B). The key difference: Pfizer Inc and Vanguard Emerging Markets Stock Index Fund ETF are close in size by market cap, and Pfizer Inc pays a 6.18% dividend while Vanguard Emerging Markets Stock Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Vanguard Emerging Markets Stock Index Fund ETF for 135 Days on average.
| PFE | VWO | |
|---|---|---|
Market Cap | $158.56B | $168.50B |
Volume | 44,138,282 | 9,650,999 |
Sector | Health | — |
52-Week High | $29.02 | $61.44 |
52-Week Low | $23.67 | $52.42 |
Typical Hold Time | 158 Days | 135 Days |
Enterprise Value | $210.06B | — |
Dividend Yield | 6.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
VWO trades at $59.76, down 0.15% on the day, with technical indicators showing a bearish bias as moving averages signal selling pressure. The ETF's emerging markets focus faces headwinds from China's economic slowdown, though AI-driven semiconductor demand in Taiwan provides some offset. Recent institutional buying by firms like Allianz and Alamar Capital suggests confidence in long-term emerging markets exposure despite near-term challenges.
The outlook remains cautious given China's persistent weakness and technical bearish signals, though institutional accumulation and AI infrastructure spending offer potential catalysts. Key risks include concentrated emerging markets exposure and currency volatility, requiring careful position sizing for investors seeking diversification beyond developed markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
